Inflammatory Bowel Disease

Entyvio and Stelara were commonly used in combination therapy for the treatment of inflammatory bowel disease, according to research at Digestive Disease Week.

Stelara and Humira demonstrated rapid onset of action and effectiveness in the treatment of patients with moderate to severe Crohn’s disease, Bruce Sands, MD, Icahn School of Medicine, told Healio Gastroenterology.

Researchers identified novel candidate biomarkers for infliximab response after unsupervised plasma proteomic analysis in pediatric patients with Crohn’s disease, according to a presentation at Digestive Disease Week.

Abivax announced positive phase 2b clinical induction and results for ABX464 in the treatment of patients with moderate to severe ulcerative colitis, according to a press release.

There was a 15-fold increase of venous thromboembolism among the pediatric inflammatory bowel disease population compared with the general population, according to presenter at Digestive Disease Week.

In this video exclusive, Florian Rieder, MD, and Jiannan Li, MD, PhD, from Cleveland Clinic, discussed a study that looked at Cadherin-11 levels in patients with inflammatory bowel disease, in particular Crohn’s disease.

Remo Panaccione, MD, University of Calgary, tells Healio Gastroenterology that Skyrizi induced clinical remission and endoscopic response in patients with Crohn’s disease, according to results from the ADVANCE and MOTIVATE trials.

In honor of World Digestive Health Day, Healio Gastroenterology presents the following report on the latest top stories from Digestive Disease Week.

The AGA published guidelines in Gastroenterology for the management of moderate-to-severe luminal and fistulizing Crohn’s disease.

Selective janus kinase 1 inhibitor, SHR0302, induced clinical response and remission among patients with moderate to severe ulcerative colitis, according to a study at Digestive Disease Week.